Outlook Therapeutics Shares Surge on Key FDA Regulatory Milestone

Investors are driving substantial gains for Outlook Therapeutics as the company achieves a critical regulatory breakthrough. The catalyst behind this market enthusiasm is the successful resubmission of the Biologics License Application for its flagship therapy, ONS-5010, which has been formally accepted for review by the U.S. Food and Drug Administration.

The primary driver behind the share price movement is the FDA’s classification of the resubmitted application as a complete, Class-1 response. This classification initiates a 60-day review period and, more significantly, has established a definitive PDUFA action date of December 31, 2025. This provides a firm timeline for a final regulatory decision, a crucial element for biotechnology investors evaluating the company’s Read more...